Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Down 72.2% in September

Virax Biolabs Group Limited (NASDAQ:VRAX) was the recipient of a significant decrease in short interest in the month of September. As of September 15th, there was short interest totalling 175,600 shares, a decrease of 72.2% from the August 31st total of 632,400 shares. Based on an average daily trading volume, of 4,500,000 shares, the short-interest ratio is presently 0.0 days. Approximately 4.3% of the company’s stock are short sold.

Virax Biolabs Group Stock Performance

VRAX stock opened at $1.93 on Wednesday. The company’s 50 day moving average price is $2.63 and its 200 day moving average price is $1.56. Virax Biolabs Group has a fifty-two week low of $0.60 and a fifty-two week high of $9.00.

Institutional Trading of Virax Biolabs Group

An institutional investor recently bought a new position in Virax Biolabs Group stock. Armistice Capital LLC bought a new position in shares of Virax Biolabs Group Limited (NASDAQ:VRAX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 121,999 shares of the company’s stock, valued at approximately $178,000. Armistice Capital LLC owned 7.87% of Virax Biolabs Group as of its most recent filing with the Securities and Exchange Commission (SEC). 8.61% of the stock is currently owned by institutional investors.

Virax Biolabs Group Company Profile

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.